CO6290702A2 - Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos - Google Patents

Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos

Info

Publication number
CO6290702A2
CO6290702A2 CO10102866A CO10102866A CO6290702A2 CO 6290702 A2 CO6290702 A2 CO 6290702A2 CO 10102866 A CO10102866 A CO 10102866A CO 10102866 A CO10102866 A CO 10102866A CO 6290702 A2 CO6290702 A2 CO 6290702A2
Authority
CO
Colombia
Prior art keywords
replicate
alfavirus
recombinants
mosquitoes
attacked
Prior art date
Application number
CO10102866A
Other languages
English (en)
Spanish (es)
Inventor
Scott C Weaver
Iiya Frolov
Elena Frolova
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of CO6290702A2 publication Critical patent/CO6290702A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CO10102866A 2008-01-24 2010-08-20 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos CO6290702A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6222908P 2008-01-24 2008-01-24

Publications (1)

Publication Number Publication Date
CO6290702A2 true CO6290702A2 (es) 2011-06-20

Family

ID=41217313

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10102866A CO6290702A2 (es) 2008-01-24 2010-08-20 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos

Country Status (15)

Country Link
US (3) US8426188B2 (OSRAM)
EP (2) EP3085787B1 (OSRAM)
JP (1) JP5758632B2 (OSRAM)
KR (2) KR101913790B1 (OSRAM)
CN (1) CN102083986B (OSRAM)
AU (1) AU2009238667A1 (OSRAM)
CA (2) CA2713165C (OSRAM)
CO (1) CO6290702A2 (OSRAM)
IL (2) IL207167A (OSRAM)
MX (3) MX367792B (OSRAM)
MY (1) MY178870A (OSRAM)
NZ (2) NZ603790A (OSRAM)
SG (2) SG187513A1 (OSRAM)
WO (1) WO2009131604A2 (OSRAM)
ZA (1) ZA201005943B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2183368T3 (pl) * 2007-06-21 2016-12-30 Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
WO2009131604A2 (en) 2008-01-24 2009-10-29 The Board Of Regents Of The University Of Texas System Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
BR112015006840A2 (pt) 2012-09-27 2017-11-21 Res Found Dev vírus chikungunya atenuado
MX361342B (es) 2013-03-14 2018-12-04 Takeda Vaccines Inc Composiciones y metodos para formulaciones de alfavirus vivos atenuados.
MX2018011839A (es) * 2016-03-31 2019-05-23 Takeda Vaccines Inc Constructos de alfavirus vivo atenuado y metodos y usos de los mismos.
PH12018502460B1 (en) * 2016-05-27 2023-11-08 Univ Griffith Arthrogenic alphavirus vaccine
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
WO2020028749A1 (en) * 2018-08-03 2020-02-06 Uab Research Foundation Methods and compositions for alphavirus vaccine
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
AU2020282369A1 (en) 2019-05-30 2022-01-20 Seattle Project Corp. Modified adenoviruses
AU2020417800A1 (en) 2019-12-31 2022-07-14 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
CA2327189A1 (en) * 2000-12-21 2002-06-21 The Minister Of National Defence Novel dna-based vaccine against the encephalitis alphaviruses
JP5016305B2 (ja) * 2003-03-20 2012-09-05 アルファヴァックス，インコーポレイテッド 改良されたアルファウイルスレプリコンおよびヘルパー構築物
US7603447B2 (en) 2004-07-30 2009-10-13 Research In Motion Limited Method and system for coordinating device setting between a communications client and its host device
US7332322B2 (en) * 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
CA2579507C (en) 2006-03-15 2017-06-13 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
WO2009131604A2 (en) * 2008-01-24 2009-10-29 The Board Of Regents Of The University Of Texas System Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Also Published As

Publication number Publication date
MX378503B (es) 2025-03-11
MX2010007989A (es) 2010-12-21
US8426188B2 (en) 2013-04-23
IL207167A (en) 2014-04-30
KR20160124255A (ko) 2016-10-26
SG10201606111XA (en) 2016-09-29
CA2910235A1 (en) 2009-10-29
KR20100106599A (ko) 2010-10-01
WO2009131604A2 (en) 2009-10-29
EP2250269B1 (en) 2016-03-16
SG187513A1 (en) 2013-02-28
EP3085787A1 (en) 2016-10-26
CA2713165A1 (en) 2009-10-29
CA2713165C (en) 2015-12-29
EP2250269A2 (en) 2010-11-17
AU2009238667A1 (en) 2009-10-29
US20110052634A1 (en) 2011-03-03
NZ603790A (en) 2014-08-29
CN102083986B (zh) 2014-06-18
US10533186B2 (en) 2020-01-14
KR101668849B1 (ko) 2016-10-24
MX2019010530A (es) 2019-10-15
ZA201005943B (en) 2011-04-28
CN102083986A (zh) 2011-06-01
MY178870A (en) 2020-10-21
WO2009131604A3 (en) 2009-12-23
NZ587502A (en) 2012-12-21
MX367792B (es) 2019-09-05
IL232032A0 (en) 2014-05-28
US9580690B2 (en) 2017-02-28
EP3085787B1 (en) 2020-10-28
US20170240919A1 (en) 2017-08-24
JP5758632B2 (ja) 2015-08-05
JP2011523347A (ja) 2011-08-11
KR101913790B1 (ko) 2018-12-28
CA2910235C (en) 2021-07-06
US20140010841A1 (en) 2014-01-09
IL207167A0 (en) 2010-12-30
EP2250269A4 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
CO6290702A2 (es) Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos
ECSP23013715A (es) Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas
PA8815301A1 (es) Ido5 antagonistas de pcsk9
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
MX2024008058A (es) Adenovirus modificados.
BR112015011244A2 (pt) Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica
CO6761348A2 (es) Compuestos antivirales
CO6420394A2 (es) Estructura tipo lamina insecticida para proteger seres humanos y animales domesticos
ECSP14013315A (es) Inhibidores de aplicación viral
BR112014032910A2 (pt) solfactants de éter de glicerina etoxilado
CU20120018A7 (es) Polipéptidos del factor ix modificados y usos de los mismos
MX385549B (es) Composición tipo azeótropo de hexafluoropropano, hexafluoropropeno y fluoruro de hidrógeno.
BR112014008616A2 (pt) compostos antivirais
AR090606A1 (es) Composicion pesticida
MX2018006373A (es) Produccion de virus en cultivos celulares.
DOP2014000034A (es) Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)
WO2012065105A3 (en) Chimeric flavivirus vaccines
CR20140040A (es) Compuestos de antranilamida y sus usos como plaguicidas
CR20140041A (es) Compuestos de antranilamida y sus usos como plaguicidas
BR112015013071A8 (pt) solução de trombina aquosa, seus métodos para liofilização e composição de trombina sólida
AR083215A1 (es) Combinacion sinergica de abamectina y bifentrina, su proceso de preparacion y uso, y metodo utilizando la misma
WO2014060851A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
ATE456303T1 (de) Verwendung von cni-sl-formulierungen zur bekämpfung der weissen fliege
UY31649A1 (es) Cierto nitrógeno que contiene entidades químicas bicíclicas para tratar infecciones virales.
CL2020002802A1 (es) 4-amino-6-(1,3-benzodioxol)picolinatos y su uso como herbicidas.

Legal Events

Date Code Title Description
FG Application granted